by Karl Voigt
In short, BU08028 is a new research drug that provides the pain relief of opiates, without their addictive effects. Trials of the drug have been conducted on rhesus monkeys with success that — it is hoped — will translate to humans. The trials, conducted at Wake Forest University School of Medicine, demonstrated a novel approach to pain relief without the risk of addiction.
Today’s pain management medicine relies primarily on opioids, like Vicodin or Oxycodone, that quell pain signals to the brain by interfering with neuron receptors known as opiod receptors, particularly the mu opioid peptide receptor (MOP). Unfortunately, these medications are highly addictive, as these MOP receptors also play a large role in regulating emotional impulses like the desire for reward, euphoria and cravings. That addiction can ultimately lead to respiratory failure and cardiac arrest.
Fortunately, the body has another type of neuron receptor called the nociceptin-orphanin FQ peptide receptor (NOP). Previous research showed that drugs that solely target NOP receptors can block the addictive effects of opioids. Building on that foundation, Wake Forest researchers created a drug that would simultaneously target both the MOP and NOP receptors to produce opioid-like pain relief while reducing the risk of addiction.
Two days ago, their findings were published in the journal Proceedings of the National Academy of Sciences. In short, monkeys were given the opportunity to self-medicate with this new drug. While the addictive nature of an opioid would make them repeatedly dose themselves, they did not do so when given the pain-killing BU08028.
While this breakthrough is impressive, the drug’s introduction is still years away. Studies on humans may start in less than two years. Find the Wake Forest abstract here.